News >

Tivozanib Improves PFS in Highly Refractory RCC

OncLive Staff
Published: Tuesday, Nov 06, 2018

Brian Rini, MD

Brian Rini, MD

The VEGF inhibitor tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma (RCC), according to topline findings from the phase III TIVO-3 trial.

In the trial, which enrolled patients who had received ≥2 prior lines of therapy, the median progression-free survival was 5.6 months with tivozanib, compared with 3.9 months with sorafenib (HR, 0.74; P = .02). The overall response rates were 18% versus 8%, respectively (P = .02).1

Overall survival (OS) data were not mature at the time of the final PFS analysis; however, the preliminary OS analysis did not show a statistically significant OS difference between the treatment arms (HR, 1.06; P = 0.69). AVEO Oncology, the manufacturer of tivozanib, plans to report additional TIVO-3 data at a future medical meeting. The company also intends to submit a new drug application to the FDA based on the TIVO-3 results, as well as data from the phase III TIVO-1 trial of tivozanib in frontline RCC.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication